Abstract:3543 Background: As important molecules in the CRC tumor microenvironment (TME), long non-coding RNAs (lncRNAs) regulate the functions of tumor infiltrating immune cells and sculpt the tumor immune microenvironment (TIME), resulting in difference in survival and response to immunotherapy among CRC patients. However, challenges remain in selecting TIME related lncRNAs (TIME-lncRNAs) of prognosis value and stratifying CRC patients for immunotherapy. Here, the aim of our study was to develop a CRC TIME-lncRNAs signature to provide survival and immunotherapy response predictions. Methods: Gene expression profiles and clinical information of CRC cases (n = 1807) were collected from 7 datasets and divided into training cohort (n = 519) and two testing cohorts (n = 595 and 693, respectively). Utilizing gene expression data of 97 immune cell lines and 61 CRC cell lines, differential expression analysis was used to identify TIME-lncRNAs. Univariate Cox regression and LASSO regression analysis were used to establish a TIME-lncRNAs signature to predict the prognosis of CRC patients. To further investigate the model, multivariate Cox regression, lncRNA-mRNA regulation analysis, gene enrichment analysis and immune infiltration analysis were carried out. The immunotherapy response predicting ability of the model was verified with an independent immunotherapy dataset. Results: Integrating the expression profiles of 10 TIME-lncRNAs, the model stratified CRC patients into low and high-score groups. Patients of the low score group had significantly prolonged survival in both training (hazard ratio (HR) = 2.63, 95% confidence interval (CI) = 1.9-3.63, P < 0.001) and testing cohorts (testing cohort 1: HR = 1.6, 95% CI = 1.19-2.16, P = 0.002; testing cohort 2: HR = 1.64, 95% CI = 1.19-2.26, P = 0.002), while higher tumor purity and less pro-tumor immune cells infiltration were also observed in the low score group. Further investigation showed that both genes differentially expressed between different groups and mRNAs regulated by 10 lncRNAs of the signature were enriched in immune-related and immunotherapy-related pathways. Multivariate Cox regression indicated that the TIME-lncRNAs signature was an independent prognosis factor. Validated with external immunotherapy dataset, the signature provided distinct predictions for patients’ responses to PD-L1 inhibitor therapy, suggesting cases of high score group could benefit more from immunotherapy. Conclusions: Based on the expression of 10 lncRNAs in the TIME, the signature makes predictions for patients’ survival and immunotherapy responses, which could help in stratifying CRC patients for immunotherapy at the bedside.

Comprehensive analysis of an immune infiltrate-related competitive endogenous RNA network reveals potential prognostic biomarkers for non-small cell lung cancer

Constructing the Cerna Regulatory Network and Combining Immune Cells to Evaluate Prognosis of Colon Cancer Patients

Identification of Candidate Biomarkers Correlated With the Pathogenesis and Prognosis of Non-small Cell Lung Cancer via Integrated Bioinformatics Analysis

The Regulatory Network and Potential Role of LINC00973-miRNA-mRNA ceRNA in the Progression of Non-Small-Cell Lung Cancer

Comprehensive analysis of ceRNA networks reveals prognostic lncRNAs related to immune infiltration in colorectal cancer

Immune Infiltration-Related ceRNA Network Revealing Potential Biomarkers for Prognosis of Head and Neck Squamous Cell Carcinoma

Comprehensive analysis of somatic mutator-derived and immune infiltrates related lncRNA signatures of genome instability reveals potential prognostic biomarkers involved in non-small cell lung cancer

Integrated analysis of lncRNA associated-competing endogenous RNAs as prognostic biomarkers in clear cell renal carcinoma.

Integrated Analysis of lncRNA-miRNA-mRNA ceRNA Network Identified lncRNA EPB41L4A-AS1 as a Potential Biomarker in Non-small Cell Lung Cancer

A novel immune-related ceRNA network that predicts prognosis and immunotherapy response in lung adenocarcinoma

A prognostic long non-coding RNA-associated competing endogenous RNA network in head and neck squamous cell carcinoma

Integrated analysis of long noncoding RNA associated-competing endogenous RNA as prognostic biomarkers in clear cell renal carcinoma

A Tumor Immune Microenvironment-Related Lncrna Signature for the Prognosis and Immunotherapeutic Sensitivity Prediction in Colorectal Cancer.

Development a Prognostic Model Integrating lncRNA/ mRNA novel Biomarkers Identified by Bioinformatics Analysis and Experiments in Breast Cancer

Immune Microenvironment Related Competitive Endogenous RNA Network As Powerful Predictors for Melanoma Prognosis Based on WGCNA Analysis.

Novel long noncoding RNA (lncRNA) panel as biomarkers for prognosis in lung squamous cell carcinoma via competitive endogenous RNA (ceRNA) network analysis

Integrative Analysis of Mrna and Mirna Expression Profiles Reveals Seven Potential Diagnostic Biomarkers for Non‑small Cell Lung Cancer

Identification of Novel Biomarkers for Predicting Prognosis and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma Based on Cerna Network and Immune Infiltration Analysis

Analysis of Lncrna-Mediated Cerna Crosstalk and Identification of Prognostic Signature in Head and Neck Squamous Cell Carcinoma.

Genome-Wide Analysis of Prognostic Lncrnas, Mirnas, and Mrnas Forming a Competing Endogenous RNA Network in Hepatocellular Carcinoma

Construction of ceRNA network to identify the lncRNA and mRNA related to non-small cell lung cancer